CD81 protein is expressed at high levels in normal germinal center B cells and in subtypes of human lymphomas.

[1]  A. Serra,et al.  Coligation of the Hepatitis C Virus Receptor CD81 with CD28 Primes Naive T Lymphocytes to Acquire Type 2 Effector Function1 , 2008, The Journal of Immunology.

[2]  Robert Tibshirani,et al.  LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Tibshirani,et al.  Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. , 2007, Blood.

[4]  Nigam H. Shah,et al.  The Stanford Tissue Microarray Database , 2007, Nucleic Acids Res..

[5]  I. Lossos,et al.  The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas. , 2007, Blood.

[6]  Randy D Gascoyne,et al.  Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Spang,et al.  A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. , 2006, The New England journal of medicine.

[8]  A. López-Guillermo,et al.  CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. , 2006, The Lancet. Oncology.

[9]  I. Lossos,et al.  Prognostic biomarkers in diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Houghton,et al.  Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[11]  R. Gascoyne,et al.  Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Lai,et al.  Hepatitis C Virus E2-CD81 Interaction Induces Hypermutation of the Immunoglobulin Gene in B Cells , 2005, Journal of Virology.

[13]  S. Levy,et al.  The tetraspanin web modulates immune-signalling complexes , 2005, Nature Reviews Immunology.

[14]  T. Golub,et al.  Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. , 2004, Blood.

[15]  Yasodha Natkunam,et al.  Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation. , 2004, Blood.

[16]  Ash A. Alizadeh,et al.  Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. , 2004, The New England journal of medicine.

[17]  R. Tibshirani,et al.  Semi-Supervised Methods to Predict Patient Survival from Gene Expression Data , 2004, PLoS biology.

[18]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.

[19]  S. Levy,et al.  The Tetraspanin CD81 Regulates the Expression of CD19 During B Cell Development in a Postendoplasmic Reticulum Compartment 1 , 2003, The Journal of Immunology.

[20]  S. Levy,et al.  Hepatitis C Virus (HCV) and Lymphomagenesis , 2003, Leukemia & lymphoma.

[21]  M. Yáñez-Mó,et al.  Cutting Edge: Dynamic Redistribution of Tetraspanin CD81 at the Central Zone of the Immune Synapse in Both T Lymphocytes and APC1 , 2002, The Journal of Immunology.

[22]  L. Staudt,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[23]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[24]  Pierre Morel,et al.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[25]  Todd,et al.  Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.

[26]  Yasodha Natkunam,et al.  Analysis of MUM1/IRF4 Protein Expression Using Tissue Microarrays and Immunohistochemistry , 2001, Modern Pathology.

[27]  D. Mason,et al.  Double immunofluorescence labelling of routinely processed paraffin sections , 2000, The Journal of pathology.

[28]  A. Børresen-Dale,et al.  Oncogenic aberrations in the p53 pathway are associated with a high S phase fraction and poor patient survival in b‐cell non‐Hodgkin's lymphoma , 2000, International journal of cancer.

[29]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[30]  M. Houghton,et al.  Binding of hepatitis C virus to CD81. , 1998, Science.

[31]  M. Inaoki,et al.  The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. , 1997, Immunity.